Feasibility Study of Stress Management and Resiliency Training (SMART) in Patients With Major Depressive Disorder.


Journal

The primary care companion for CNS disorders
ISSN: 2155-7780
Titre abrégé: Prim Care Companion CNS Disord
Pays: United States
ID NLM: 101547532

Informations de publication

Date de publication:
30 Apr 2020
Historique:
received: 17 10 2019
accepted: 17 01 2020
entrez: 6 5 2020
pubmed: 6 5 2020
medline: 9 6 2021
Statut: epublish

Résumé

Stress is associated with the onset, maintenance, and recurrence of depression. This study investigated the feasibility of stress management and resiliency training (SMART) for enhancing resiliency in a group of patients with major depressive disorder. In an open-label study, patients with major depressive disorder were invited to participate in an adjunctive 8-week group therapy of SMART (from June 2017 to June 2018) that encompassed attention training and practice of gratitude, compassion, higher meaning, acceptance, and forgiveness. The primary outcome measure was baseline-to-endpoint change in resilience as measured by the Connor Davidson Resilience Scale (CD-RISC). Secondary outcome measures included baseline-to-endpoint change in stress using the Perceived Stress Scale (PSS) and in depression using the 17-item Hamilton Depression Rating Scale (HDRS-17) and 9-item Patient Health Questionnaire (PHQ-9). Twenty-three participants enrolled in the study (mean ± SD age = 46 ± 13 years, female = 91%). Baseline ratings of mood were of mild-to-moderate symptom severity (mean HDRS-17 score = 14.5 and PHQ-9 score = 12), resilience (mean CD-RISC score = 53.8), and perceived stress (mean PSS score = 23.5). Of the participants, 74% were study completers (attended ≥ 6 sessions). In an intention-to-treat analysis, at study endpoint there was a significant improvement in resilience (mean CD-RISC score = 61.1, P = .03), reduction in perceived stress (mean PSS score = 19.4, P = .002), and improvement in depression (mean HDRS-17 score = 9.1 and PHQ-9 score = 7.6, both P < .001). A resilience training program focused on wellness is feasible for patients who are currently symptomatic with major depressive disorder. A larger randomized controlled trial is needed to establish efficacy of this intervention and explore the long-term impact of stress management and resilience training in depression. ClinicalTrials.gov identifier: NCT03275961.

Identifiants

pubmed: 32369689
doi: 10.4088/PCC.19m02556
doi:
pii:

Banques de données

ClinicalTrials.gov
['NCT03275961']

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Copyright 2020 Physicians Postgraduate Press, Inc.

Auteurs

Ashok Seshadri (A)

Department of Psychiatry and Psychology, Mayo Clinic, 1000 First Drive NW, Austin, Minnesota 55912. Seshadri.Ashok@mayo.edu.
Departments of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
School of Psychology, Deakin University, Geelong, Melbourne, Australia.

Matthew M Clark (MM)

Departments of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.

Simon Kung (S)

Departments of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.

Matthew Fuller-Tyszkiewicz (M)

School of Psychology, Deakin University, Geelong, Melbourne, Australia.

Amit Sood (A)

Department of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Global Center for Resiliency and Wellbeing, Rochester, Minnesota, USA.

Kristina C Dammen (KC)

Departments of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.

Jose A Rico (JA)

Departments of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.

Susannah J Tye (SJ)

Queensland Brain Institute, University of Queensland, St Lucia, Queensland, Australia.

Jane McGillivray (J)

School of Psychology, Deakin University, Geelong, Melbourne, Australia.

Mark A Frye (MA)

Departments of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH